Artiva Biotherapeutics, Inc.
ARTV- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001817241
In the last 90 days, Artiva Biotherapeutics, Inc. insiders filed 0 open-market purchases and 16 sales; 72 institutions reported holding it in 13F filings for Q2 2026, worth $391.6M in total; Viking Global Investors is the only superinvestor holding it.
Key figures
- Market capClose on Nov 11, 2026
- $201.2M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $2.34M in total
- 16
- 13F holdersQ2 2026, +32 vs. previous quarter
- 72
- 13F valueReported value at the end of Q2 2026
- $391.6M
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $0
- −100.0% year over year
- Net income, FY2025
- -$83.9M
- No comparable prior period
- Free cash flow, FY2025
- -$79.3M
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 2.95M
- Shares sold short
- Change
- +215.9K
- +7.9% vs. previous
- Days to cover
- 1.81
- At average daily volume
Superinvestors holding ARTV, Q2 2026
Go to the superinvestors tab1 superinvestor reports holding Artiva Biotherapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Viking Global Investors
Andreas Halvorsen
0.1%
Artiva Biotherapeutics, Inc.'s share of the portfolio
- Shares
- 2,604,166
- Value
- $25.3M
Latest insider trades
See all insider tradesOpen-market purchases and sales by Artiva Biotherapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 3, 2026 (view filing)4:05 PM ET | Nov 2 | 1 day | Horan ChristopherChief Tech Operations Officer | SSale | −10.4K | $4.18 | −$43.6K | −3.3%302.3K after | |
| Nov 3, 2026 (view filing)4:05 PM ET | Nov 2 | 1 day | Bush JenniferCOO, CLO, Compliance Officer | SSale | −8.44K | $4.18 | −$35.3K | −2.3%357.7K after | |
| Nov 3, 2026 (view filing)4:04 PM ET | Nov 2 | 1 day | Banerjee SubhashisChief Medical Officer | SSale | −1.11K | $4.18 | −$4.64K | −0.7%168.7K after | |
| Nov 3, 2026 (view filing)4:04 PM ET | Nov 2 | 1 day | Aslan FredChief Executive Officer | SSale | −62.2K | $4.18 | −$260.0K | −4.1%1.46M after | |
| Oct 7, 2026 (view filing)4:02 PM ET | Oct 6 | 1 day | Aslan FredChief Executive Officer | SSale | −23.5K | $7.20 | −$168.9K | −1.5%1.52M after | 10b5-1 |
| Oct 6, 2026 (view filing)4:02 PM ET | Oct 5 | 1 day | Horan ChristopherChief Tech Operations Officer | SSale | −10.3K | $6.84 | −$70.7K | −3.2%312.7K after | |
| Oct 6, 2026 (view filing)4:02 PM ET | Oct 5 | 1 day | Bush JenniferCOO, CLO, Compliance Officer | SSale | −8.37K | $6.84 | −$57.2K | −2.2%366.2K after | |
| Oct 6, 2026 (view filing)4:02 PM ET | Oct 5 | 1 day | Banerjee SubhashisChief Medical Officer | SSale | −1.10K | $6.84 | −$7.51K | −0.6%169.8K after | |
| Oct 6, 2026 (view filing)4:01 PM ET | Oct 5 | 1 day | Aslan FredChief Executive Officer | SSale | −61.7K | $6.84 | −$421.8K | −3.8%1.54M after | |
| Sep 9, 2026 (view filing)4:02 PM ET | Sep 8 | 1 day | Aslan FredChief Executive Officer | SSale | −23.4K | $10.92 | −$255.7K | −1.6%1.45M after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 72 holdersThe largest institutional positions in Artiva Biotherapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 17,955,642 | $174.2M | 1.51% | +8,102,340+82.2% | Added |
| Viking Global Investors LPSuperinvestorViking Global Investors | 2,604,166 | $25.3M | 0.07% | +2,604,166 | New |
| Blackstone Group Inc. | 2,403,437 | $23.3M | 0.06% | +2,403,437 | New |
| 5AM Venture Management, LLC | 2,353,304 | $22.8M | 7.93% | 00.0% | Unchanged |
| VR Adviser, LLC | 2,043,596 | $19.8M | 0.60% | +434,027+27.0% | Added |
| Franklin Resources Inc | 1,997,223 | $19.4M | 0.00% | +1,476,896+283.8% | Added |
| Caligan Partners LP | 1,736,111 | $16.8M | 0.81% | +1,736,111 | New |
| Vanguard Capital Management LLC | 981,815 | $9.52M | 0.00% | +774,129+372.7% | Added |
| Samsara BioCapital, LLC | 954,861 | $9.26M | 0.76% | +954,861 | New |
| Blue Owl Capital Holdings LP | 874,542 | $8.48M | 1.29% | +874,542 | New |
Holders of 5% or more of ARTV
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Artiva Biotherapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 13D/A | 37.90%18.4M shares | +1.30 ppfrom 36.60% | Jul 29, 20245 filings | Jul 23, 2026 | SEC |
| GC Corp. | 13D/A | 12.30%6.00M shares | – | Jul 29, 20242 filings | May 28, 2026 | SEC |
| Viking Global Investors LPSuperinvestorViking Global Investors | 13G | 5.40%2.60M shares | New | May 18, 20261 filing | May 18, 2026 | SEC |